Summit Therapeutics (NASDAQ:SMMT) PT Raised to $25.00

Summit Therapeutics (NASDAQ:SMMT – Free Report) had its price target raised by Stifel Nicolaus from $14.00 to $25.00 in a research report released on Monday, Benzinga reports. They currently have a buy rating on the stock. Other equities analysts also recently issued reports about the stock. Citigroup raised their target price on shares of Summit […]